1 / 10

Techne Corp . (TECH)

Techne Corp . (TECH). Brenton Wanner. Overview. Research and Diagnostic Systems, Inc. Minneapolis, Minnesota R&D Systems Europe Ltd. Abingdon, England Dev. and manu . hematology controls Check accuracy of blood analysis instruments. Key Stats. Recent Price : $60.36

nemo
Télécharger la présentation

Techne Corp . (TECH)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Techne Corp. (TECH) BrentonWanner

  2. Overview • Research and Diagnostic Systems, Inc. • Minneapolis, Minnesota • R&D Systems Europe Ltd. • Abingdon, England • Dev. and manu. hematology controls • Check accuracy of blood analysis instruments

  3. Key Stats • Recent Price : $60.36 • Purchase Price : $69.78 • Intrinsic Value : N/A • Shares : 40 • Gain : ($376.80) • Port Weight: 3.51% • P/E: 20.5 • Debt/Equity: N/A • EPS Growth 3 Yr: 8.85 • Net Profit Margin: 40.8 • ROE: 22.91

  4. Techne Industry • P/E: 20.5 • P/B: 4.3 • EPS Growth (3yr Avg): 11.0 • Net Profit Margin: 40.8 • ROE: 22.9 • Debt/Equity: 0.0 • P/E: 26.1 • P/B: 2.8 • EPS Growth (3yr Avg): 16.2 • Net Profit Margin: 3.2 • ROE: 3.7 • Debt/Equity: 0.5 Industry comparison

  5. 1 yr. Graph

  6. 5 yr. Graph

  7. Recent News • Techne Corporation Declares Dividend (10-28-10) • Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2011 (10-26-10) • BioInformatics, LLC New Market Reports - RNAi, Genomics and Membrane Protein Structure (10-14-10)

  8. Analyst’s Recommendation • Total Number of Analysts: 5 • Strong Buy: 3 • Buy: 1 • Hold: 1 • Underperform: 0 • Sell: 0

  9. Future Estimates • Revenue expected to rise from 280.64B to 300.01B • EPS expected to rise from 2.95 to 3.02 • Growth next 5 years: 10.67%

  10. Recommendation We should sell TECH because the company has bad financial ratios, institutional investment has decreased significantly, and is estimated to have little to no growth within the next 10 years. The company is banking off its subsidiary in China which does put them in a position for potential long term growth.

More Related